Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Profit After Tax (2022 - 2026)

Sagimet Biosciences' Profit After Tax history spans 5 years, with the latest figure at -$10.6 million for Q1 2026.

  • Quarterly Profit After Tax rose 41.41% to -$10.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$43.5 million through Mar 2026, up 23.82% year-over-year, with the annual reading at -$51.0 million for FY2025, 12.01% down from the prior year.
  • Profit After Tax came in at -$10.6 million for Q1 2026, down from -$9.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$6.4 million in Q3 2023 to a low of -$18.2 million in Q1 2025.
  • The 5-year median for Profit After Tax is -$8.1 million (2023), against an average of -$9.8 million.
  • Year-over-year, Profit After Tax tumbled 174.19% in 2025 and then surged 41.41% in 2026.
  • Sagimet Biosciences' Profit After Tax stood at -$7.2 million in 2022, then dropped by 13.22% to -$8.2 million in 2023, then crashed by 98.76% to -$16.2 million in 2024, then surged by 40.94% to -$9.6 million in 2025, then fell by 11.31% to -$10.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Profit After Tax are -$10.6 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025).